Teriflunomide for the treatment of multiple sclerosis

Clinical Neurology and Neurosurgery

Volumn 115, Issue SUPPL.1, 2013, Pages

  Warnke, Clemens ^a   Stüve, Olaf ^b,c   Kieseier, Bernd C ^a  

^a Department of Orthopedic Surgery   (Germany)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Immunotherapy; Multiple sclerosis; Oral; Teriflunomide

Indexed keywords

ALANINE AMINOTRANSFERASE; CELL ADHESION MOLECULE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEFLUNOMIDE; MATRIX METALLOPROTEINASE; MYELIN BASIC PROTEIN; PHENYTOIN; TERIFLUNOMIDE; TUMOR NECROSIS FACTOR ALPHA; WARFARIN;

ABDOMINAL PAIN; ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ALOPECIA; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD CELL COUNT; CELL ACTIVATION; CELL PROLIFERATION; CONDYLOMA ACUMINATUM; CYTOKINE PRODUCTION; DEMYELINATION; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DYSPEPSIA; ENTEROHEPATIC CIRCULATION; ERYTHEMA MULTIFORME; EXPANDED DISABILITY STATUS SCALE; HEADACHE; HELPER CELL; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LIMB PAIN; LIVER DYSFUNCTION; MOTOR DYSFUNCTION; MOUTH ULCER; MULTIPLE SCLEROSIS; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RELAPSE; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENESIS; TRIGEMINUS NEURALGIA; URTICARIA; WEIGHT REDUCTION;

IMMUNOTHERAPY; MULTIPLE SCLEROSIS; ORAL; TERIFLUNOMIDE;

ADMINISTRATION, ORAL; ANIMALS; CLINICAL TRIALS AS TOPIC; CROTONATES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; RECURRENCE; TOLUIDINES;

EID: 84890054384     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2013.09.030     Document Type: Article

References (63)

1. Multiple Sclerosis Therapy Consensus Group (MSTCG), H. Wiendl, K.V. Toyka, P. Rieckmann, R. Gold, and H.P. Hartung Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations J Neurol 255 10 2008 1449 1463
2. R.M. Ransohoff Natalizumab for multiple sclerosis N Engl J Med 356 25 2007 2622 2629
3. G.P.A. Rice, H. Hartung, and P.A. Calabresi Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale Neurology 64 8 2005 1336 1342
4. C.H. Polman, P.W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, and D.H. Miller A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 9 2006 899 910
5. R.A. Rudick, W.H. Stuart, P.A. Calabresi, C. Confavreux, S.L. Galetta, and E.W. Radue Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 9 2006 911 923
6. B.K. Kleinschmidt-DeMasters, and K.L. Tyler Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis N Engl J Med 353 4 2005 369 374
7. A. Langer-Gould, S.W. Atlas, A.J. Green, A.W. Bollen, and D. Pelletier Progressive multifocal leukoencephalopathy in a patient treated with natalizumab N Engl J Med 353 4 2005 375 381
8. G. Van Assche, M. Van Ranst, R. Sciot, B. Dubois, S. Vermeire, and M. Noman Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease N Engl J Med 353 4 2005 362 368
9. H. Hartung New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab Lancet Neurol 8 1 2009 28 31
10. D96A171A-3815-4766-940D-BE6E2DAD8F0A-biibTysabri13Mar09.pdf (application/pdf Object). Available at: http://library.corporate-ir.net/library/ 14/148/148682/items/328677/D96A171A-3815-4766-940D-BE6E2DAD8F0A- biibTysabri13Mar09.pdf [Accessed March 17, 2009].
11. S.M. Kranick, E.M. Mowry, and M.R. Rosenfeld Progressive multifocal leukoencephalopathy after rituximab in a case of non-Hodgkin lymphoma Neurology 69 7 2007 704 706
12. S.I. Martin, F.M. Marty, K. Fiumara, S.P. Treon, J.G. Gribben, and L.R. Baden Infectious complications associated with alemtuzumab use for lymphoproliferative disorders Clin Infect Dis 43 1 2006 16 24
13. CAMMS223 Trial Investigators, A.J. Coles, D.A. Compston, K.W. Selmaj, S.L. Lake, and S. Moran Alemtuzumab vs. interferon beta-1a in early multiple sclerosis N Engl J Med 359 17 2008 1786 1801
14. B.C. Kieseier, and H. Wiendl Oral disease-modifying treatments for multiple sclerosis: the story so far CNS Drugs 21 6 2007 483 502
15. L. Osterberg, and T. Blaschke Adherence to medication N Engl J Med 353 5 2005 487 497
16. E. Tallantyre, N. Evangelou, and C.S. Constantinescu Spotlight on teriflunomide Int MS J 15 2 2008 62 68
17. E.K. Li, L. Tam, and B. Tomlinson Leflunomide in the treatment of rheumatoid arthritis Clin Ther 26 4 2004 447 459
18. P. Maddison, P. Kiely, B. Kirkham, T. Lawson, R. Moots, and D. Proudfoot Leflunomide in rheumatoid arthritis: recommendations through a process of consensus Rheumatology (Oxford) 44 3 2005 280 286
19. M. Osiri, B. Shea, V. Robinson, M. Suarez-Almazor, V. Strand, and P. Tugwell Leflunomide for treating rheumatoid arthritis CDS Rev 1 2003 CD002047
20. B. Rozman Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators' Group J Rheumatol Suppl 53 1998 27 32
21. J.M. Bruneau, C.M. Yea, S. Spinella-Jaegle, C. Fudali, K. Woodward, and P.A. Robson Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide Biochem J 336 Pt 2 1998 299 303
22. R.I. Fox Mechanism of action of leflunomide in rheumatoid arthritis J Rheumatol Suppl 53 1998 20 26
23. D.E. Furst, and Leflunomide mycophenolic acid and matrix metalloproteinase inhibitors Rheumatology (Oxford) 38 Suppl. 2 1999 14 18
24. S. Greene, K. Watanabe, J. Braatz-Trulson, and L. Lou Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide Biochem Pharmacol 50 6 1995 861 867
25. H.M. Cherwinski, D. McCarley, R. Schatzman, B. Devens, and J.T. Ransom The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism J Pharmacol Exp Ther 272 1 1995 460 468
26. R.I. Fox, M.L. Herrmann, C.G. Frangou, G.M. Wahl, R.E. Morris, and V. Strand Mechanism of action for leflunomide in rheumatoid arthritis Clin Immunol 93 3 1999 198 208
27. X. Xu, J.W. Williams, E.G. Bremer, A. Finnegan, and A.S. Chong Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide J Biol Chem 270 21 1995 12398 12403
28. X. Xu, L. Blinder, J. Shen, H. Gong, A. Finnegan, and J.W. Williams In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice J Immunol 159 1 1997 167 174
29. M. Zeyda, M. Poglitsch, R. Geyeregger, J.S. Smolen, G.J. Zlabinger, and W.H. Hörl Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation Arthritis Rheum 52 9 2005 2730 2739
30. S.K. Manna, and B.B. Aggarwal Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression J Immunol 162 4 1999 2095 2102
31. V. Déage, D. Burger, and J.M. Dayer Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases Eur Cytokine Netw 9 4 1998 663 668
32. M.C. Kraan, R.J. Reece, E.C. Barg, T.J. Smeets, J. Farnell, and R. Rosenburg Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers Arthritis Rheum 43 8 2000 1820 1830
33. D. Burger, N. Begué-Pastor, and S. Benavent The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes Rheumatology (Oxford) 42 1 2003 89 96
34. W.W. Cao, P.N. Kao, Y. Aoki, J.C. Xu, R.A. Shorthouse, and R.E. Morris A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2 Transplant Proc 28 6 1996 3079 3080
35. L.C. Hamilton, I. Vojnovic, and T.D. Warner A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner Br J Pharmacol 127 7 1999 1589 1596
36. arava.pdf (application/pdf Object). Available at: http://products.sanofi- aventis.us/arava/arava.pdf [Accessed March 18, 2009].
37. J.M. Beaman, L.P. Hackett, G. Luxton, and K.F. Illett Effect of hemodialysis on leflunomide plasma concentrations Ann Pharmacother 36 1 2002 75 77
38. T. Korn, T. Magnus, K. Toyka, and S. Jung Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide - mechanisms independent of pyrimidine depletion J Leukoc Biol 76 5 2004 950 960
39. J.E. Merrill, S. Hanak, S.F. Pu, J. Liang, C. Dang, and D. Iglesias-Bregna Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis J Neurol 256 1 2009 89 103
40. H.F. McFarland, and R. Martin Multiple sclerosis: a complicated picture of autoimmunity Nat Immunol 8 9 2007 913 919
41. P.W. O'Connor, D. Li, M.S. Freedman, A. Bar-Or, G.P. Rice, and C. Confavreux A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses Neurology 66 6 2006 894 900
42. J.F. Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 11 1983 1444 1452
43. D.W. Paty, J.J. Oger, L.F. Kastrukoff, S.A. Hashimoto, J.P. Hooge, and A.A. Eisen MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT Neurology 38 2 1988 180 185
44. C.M. Poser, D.W. Paty, L. Scheinberg, W.I. McDonald, F.A. Davis, and G.C. Ebers New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann Neurol 13 3 1983 227 231
45. V. Mladenovic, Z. Domljan, B. Rozman, I. Jajic, D. Mihajlovic, and J. Dordevic Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study Arthritis Rheum 38 11 1995 1595 1603
46. J.S. Smolen, J.R. Kalden, D.L. Scott, B. Rozman, T.K. Kvien, and A. Larsen Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group Lancet 353 9149 1999 259 266
47. V. Strand, S. Cohen, M. Schiff, A. Weaver, R. Fleischmann, and G. Cannon Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group Arch Intern Med 159 21 1999 2542 2550
48. P.L. van Riel, J.S. Smolen, P. Emery, J.R. Kalden, M. Dougados, and C.V. Strand Leflunomide: a manageable safety profile J Rheumatol Suppl 71 2004 21 24
49. arava-deardoc.pdf (application/pdf Object). Available at: http://www.fda.gov/medwatch/SAFETY/2003/arava-deardoc.pdf [Accessed March 18, 2009].
50. P. Emery, F.C. Breedveld, E.M. Lemmel, J.P. Kaltwasser, P.T. Dawes, and B. Gömör A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis Rheumatology (Oxford) 39 6 2000 655 665
51. J. Auer, M. Hinterreiter, S. Allinger, A. Kirchgatterer, and P. Knoflach Severe pancytopenia after leflunomide in rheumatoid arthritis Acta Med Austriaca 27 4 2000 131 132
52. R.L. Hill, D.J. Topliss, and P.M. Purcell Pancytopenia associated with leflunomide and methotrexate Ann Pharmacother 37 1 2003 149
53. J.R. Kalden, M. Schattenkirchner, and H. Sörensen The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study Arthritis Rheum 48 6 2003 1513 1520
54. K.A. Jenks, L.K. Stamp, J.L. O'Donnell, R.L. Savage, and P.T. Chapman Leflunomide-associated infections in rheumatoid arthritis J Rheumatol 34 11 2007 2201 2203
55. K. Warnatz, H.H. Peter, M. Schumacher, L. Wiese, A. Prasse, and F. Petschner Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature Ann Rheum Dis 62 1 2003 50 57
56. B. Rozman, S. Praprotnik, D. Logar, M. Tomsic, M. Hojnik, and M. Kos-Golja Leflunomide and hypertension Ann Rheum Dis 61 6 2002 567 569
57. R. Fukushima, S. Kanamori, M. Hirashiba, A. Hishikawa, R. Muranaka, and M. Kaneto Inhibiting the teratogenicity of the immuno-suppressant leflunomide in mice by supplementation of exogenous uridine Toxicol Sci 108 2 2009 419 426
58. R. Fukushima, S. Kanamori, M. Hirashiba, A. Hishikawa, R. Muranaka, and M. Kaneto Critical periods for the teratogenicity of immune-suppressant Leflunomide in mice Congenit Anom (Kyoto) 49 1 2009 20 26
59. R. Fukushima, S. Kanamori, M. Hirashiba, A. Hishikawa, R.I. Muranaka, and M. Kaneto Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice Reprod Toxicol 24 3-4 2007 310 316
60. P. O'Connor, J.S. Wolinsky, C. Confavreux, G. Comi, L. Kappos, and T.P. Olsson Randomized trial of oral teriflunomide for relapsing multiple sclerosis N Engl J Med 365 2011 1293 1303
61. J.S. Wolinsky, P.A. Narayana, F. Nelson, S. Datta, P. O'Connor, and C. Confavreux Magnetic resonance imaging outcomes from a phase III trial of teriflunomide Mult Scler. 19 10 2013 1310 1319
62. C. Warnke, G. Meyer zu Hörste, H.P. Hartung, O. Stüve, and B.C. Kieseier Review of teriflunomide and its potential in the treatment of multiple sclerosis Neuropsych Dis Treat 5 2009 333 340
63. C. Warnke, G. Meyer Zu Hörste, T. Menge, O. Stüve, H.P. Hartung, and H. Wiendl Nervenarzt 84 2013 724 731